Inflazome
Jeremy Skillington is the Vice President of Business Development at Inflazome. Jeremy has held this position since July 2016. Prior to Inflazome, Jeremy was with Trinity College Dublin as a business development consultant. From July 2015 to December 2019, they were with ethris GmbH as their business development director. And from September 2014 to December 2019, they were an entrepreneur in residence at HS Lifescience. Jeremy is also the co-founder and CEO of TriMod Therapeutics and the Senior Director of Business Development at Opsona Therapeutics.
Jeremy Skillington has a PhD and BSc in Biochemistry from the National University of Ireland, Galway.
Some of their coworkers include Luke O'Neill - Co-founder & Chief Scientific Officer, Conor Dalton - Finance Director, and Thomas Jung - Chief Medical Officer. Jeremy Skillington reports to Dr. Matthew Cooper, Co-founder and Chief Executive Officer.
This person is not in any offices
Inflazome
Inflammasomes generate signals that cause immune cells to fight infections. Usually this is beneficial, but unwanted inflammation can happen when immune cells become activated without control.